Shukra Pharmaceuticals manufactures and trades pharmaceutical formulations and provides laboratory testing services for domestic and international markets. The company produces a wide range of generic medicines including antibiotics, anti-virals, and analgesics.
The company lacks a durable moat, as evidenced by volatile margins and a low average ROCE of 10% which barely covers the cost of capital. While they possess WHO-GMP certifications, these are standard regulatory requirements for the industry rather than a source of competitive advantage, and the high cash conversion cycle suggests weak bargaining power with customers.
Management has prioritized bonus share issues and stock splits over meaningful dividend growth or high-return reinvestment. The low cash conversion ratio (0.37) indicates that capital is increasingly tied up in working capital rather than generating free cash flow for shareholders.
The investment collapsed as the disconnect between reported accounting profits and actual cash generation became unsustainable. Management continued to funnel capital into interest-free loans for related parties while ignoring statutory compliance, eventually triggering regulatory crackdowns and delisting threats. As working capital bloated and the cash conversion ratio remained abysmal, the company lacked the liquidity to modernize facilities, causing it to lose its standard certifications and fall behind more disciplined generic competitors.
RichFakir rates Shukra Pharmaceuticals Ltd's business quality as poor — 37/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Shukra Pharmaceuticals Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Shukra Pharmaceuticals Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Shukra Pharmaceuticals Ltd's fair value is about ₹3 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →